← Leaderboards
Yibin Deng
University Of Minnesota
$4,325,572
Attributed
$4,696,530
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $626.4K · FY2007–23$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,696,530 · 5
By mechanism
R01$3,189,780 · 2
K01$764,833 · 1
R21$741,917 · 2
Top collaborators
- Junxuan Lu4 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMediatingMolecularPlayTp53 GeneComplexBaseGenerationsMalignant NeoplasmsTissuesPathway InteractionsMouse ModelResearch StudyMolecular TargetPreventResponseCohortApoptoticApoptosisTumorIn VitroIncidenceMutationFunctional Disorder
Grant awards (20)
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer$386,744
R01 · FY2023 · CA · contact PI
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer$386,744
R01 · FY2022 · CA · contact PI
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer$394,636
R01 · FY2021 · CA · contact PI
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer$394,636
R01 · FY2020 · CA · contact PI
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer$406,786
R01 · FY2019 · CA · contact PI
Translational development studies of a novel combination therapy for castration-resistant prostate cancer$162,680
R21 · FY2019 · CA
Translational development studies of a novel combination therapy for castration-resistant prostate cancer$214,380
R21 · FY2018 · CA
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesis$246,301
R01 · FY2015 · CA · contact PI
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesis$306,945
R01 · FY2014 · CA · contact PI
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesis$45,006
R01 · FY2013 · CA · contact PI
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesis$314,259
R01 · FY2012 · CA · contact PI
Prevention of PTEN deletion driven prostate cancer by selenium$165,844
R21 · FY2012 · CA · contact PI
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesis$307,723
R01 · FY2011 · CA · contact PI
Prevention of PTEN deletion driven prostate cancer by selenium$199,013
R21 · FY2011 · CA
Telomere dysfunction, p53 and tumorigenesis$119,695
K01 · FY2011 · CA · contact PI
Telomere dysfunction, p53 and tumorigenesis$154,984
K01 · FY2010 · CA · contact PI
Telomere dysfunction, p53 and tumorigenesis$151,832
K01 · FY2009 · CA · contact PI
Telomere dysfunction, p53 and tumorigenesis$92,114
K01 · FY2009 · CA · contact PI
Telomere dysfunction, p53 and tumorigenesis$124,552
K01 · FY2008 · CA · contact PI
Telomere dysfunction, p53 and tumorigenesis$121,656
K01 · FY2007 · CA · contact PI